Syngene International Ltd. (BSE: 539268, NSE: SYNGENE, ISIN: INE398R01022) is an integrated research, development, and manufacturing services company serving the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical sectors.
Syngene's more than 6000 scientists offer both skills and the capacity to deliver great science, robust data security, and quality manufacturing, at speed, to improve time-to-market and lower the cost of innovation. With a combination of dedicated research facilities for Amgen, Baxter, and Bristol-Myers Squibb as well as 2 Mn sq.ft of specialist discovery, development and manufacturing facilities, Syngene works with biotech companies pursuing leading-edge science as well as multinationals, including GSK, Zoetis and Merck KGaA.
For more details, visit www.syngeneintl.com or write to us at bdc@syngeneintl.com
Shared 1 month ago
44 views
Shared 2 months ago
298 views
Shared 2 months ago
35 views
Shared 2 months ago
52 views
Shared 2 months ago
127 views
Shared 3 months ago
75 views
Shared 4 months ago
74 views
Shared 5 months ago
320 views
Shared 7 months ago
61 views
Shared 8 months ago
160 views
Shared 9 months ago
32 views
Shared 1 year ago
247 views
Shared 1 year ago
97 views
Shared 1 year ago
140 views
Shared 1 year ago
395 views
Shared 2 years ago
452 views
Shared 2 years ago
197 views
Shared 2 years ago
4.2K views
Shared 2 years ago
838 views
Shared 2 years ago
367 views
Shared 2 years ago
294 views
Shared 2 years ago
361 views
Shared 2 years ago
497 views
Shared 2 years ago
454 views
Shared 2 years ago
277 views
Ensure regulatory-grade Safety profile of your lead compound | In Vitro & Genetic Toxicology #shorts
Shared 2 years ago
187 views
Shared 2 years ago
101K views
Shared 3 years ago
432 views
Shared 3 years ago
878 views
Shared 3 years ago
276 views
Shared 3 years ago
1.4K views
Shared 3 years ago
2.6K views